Olmesartan medoxomil: Influence of age, renal and hepatic function on the pharmacokinetics of olmesartan medoxomil

Journal of Hypertension, Supplement

Volumn 19, Issue 1, 2001, Pages

  Von Bergmann, K ^a   Laeis, P ^a   Puchler K ^a   Sudhop, T ^a   Schwocho, L R ^a   Gonzalez, L ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Age; Hepatic impairment; Olmesartan; Olmesartan medoxomil; Pharmacokinetic; Renally impairment

Indexed keywords

ANTIHYPERTENSIVE AGENT; OLMESARTAN; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; AREA UNDER THE CURVE; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; FEMALE; HUMAN; KIDNEY FUNCTION; LIVER FUNCTION; MALE; PRIORITY JOURNAL; REVIEW; STEADY STATE;

AGED; AGING; ANTIHYPERTENSIVE AGENTS; FEMALE; HUMANS; HYPERTENSION; IMIDAZOLES; KIDNEY; LIVER; MALE; MIDDLE AGED; REFERENCE VALUES; TETRAZOLES;

EID: 0034961923     PISSN: 09521178     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (6)

1. Blood pressure and endocrine effects of single doses of CS-866, a novel angiotensin II-antagonist, in salt restricted, hypertensive patients
2. Antihypertensive efficacy of CS-866, a novel angiotensin II-antagonist
3. The pharmacokinetic profile of CS-866
4. The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction
5. Transection of the oesophagus for bleeding oesophageal varices
6. Superiority of the Child-Pugh classification to quantitative liver function tests for assessing prognosis of liver cirrhosis